4.5 Article

Treatment of primary aldosteronism

Journal

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.beem.2010.10.001

Keywords

primary aldosteronism; mineralocorticoid receptor; adrenalectomy; spironolactone; eplerenone; conn's adenoma

Funding

  1. National Institute for Health Research [NF-SI-0508-10356] Funding Source: researchfish

Ask authors/readers for more resources

The prevalence of primary hyperaldosteronism approaches 10% of all hypertensive patients, and besides efficient diagnostic procedures, effective treatment is of increasing importance to reverse increased morbidity and mortality. Aldosterone-producing adenoma and unilateral adrenal hyperplasia are amenable to cure by endoscopic adrenalectomy. Bilateral adrenal hyperplasia (micro- or macronodular), which comprises two-thirds of primary hyperaldosteronism, is treated primarily by mineralocorticoid receptor antagonists (starting dose 12.5-25 mg/day spironolactone with titration up to 100 mg/day, alternatively 50-100 mg/day eplerenone). If blood pressure is not normalised by this first-line treatment, additional treatment with potassium-sparing diuretics (amiloride or triamterene) or calcium channel antagonists is necessary. The start of medication should be closely monitored by serum electrolyte and creatinine controls. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available